Takeda Presents Long-Term Data From Phase 3 Advance-Cidp 3 Clinical Trial of Hyqvia® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) at Pns Annual Meeting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.